Tuesday, March 2, 2021

Brazil halts trials of Chinese Covid-19 vaccine

Anvisa says it 'ruled to interrupt the clinical trial of the CoronaVac vaccine after a serious adverse incident' on Oct 29.

Other News

Tabung Haji umum dividen 3.1%, meningkat berbanding 2019

Agihan keuntungan bagi tahun 2020 melibatkan jumlah sebanyak RM2.24 bilion berbanding RM2.14 bilion pada tahun 2019.

Tabung Haji announces profit distribution of 3.10%

The 2020 profit distribution involves a total payout of RM2.24 billion against RM2.14 billion in 2019.

Proton market share hits 7-year high with 11,873 units delivered in February

Proton finished the month ranked second in Malaysia with sales nearly doubling the January 2021 total of 5,964 units.

Rise of ‘underdog’ Muhyiddin puts to rest debate on ‘Mahathir or Anwar’, says analyst

With the opposition in disarray, the prime minister's brand may just work in the next polls.

Ahli Parlimen Putatan Awang Husaini nafi keluar PKR

Awang nasihatkan ahli PKR untuk tidak mempercayai tuduhan beliau lompat parti.

Brazil’s health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an “adverse incident” involving a volunteer recipient, a blow for one of the most advanced vaccine candidates.

The setback for CoronaVac, developed by Chinese pharmaceutical firm Sinovac Biotech, came on the same day US pharmaceutical giant Pfizer said its own vaccine candidate had shown 90% effectiveness, sending global markets soaring and raising hopes of an end to the pandemic.

The Brazilian regulator, Anvisa, said in a statement it had “ruled to interrupt the clinical study of the CoronaVac vaccine after a serious adverse incident” on Oct 29.

It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalisation, birth defects and other “clinically significant events.”

Sinovac, however, said the incident was “not related to the vaccine”, adding that it will “continue to communicate with Brazil on this matter”.

The public health centre coordinating the trials of the vaccine in Brazil, the Butantan Institute, said it was “surprised” by the decision.

The institute “is investigating in detail what happened”, and “is at the Brazilian regulatory agency’s disposal to provide any clarification necessary on any adverse incident the clinical trials may have presented”, it said.

It said it would hold a press conference on Tuesday at 11am (1400 GMT).

CoronaVac has been caught up in a messy political battle in Brazil, where its most visible backer has been Sao Paulo Governor Joao Doria, a top opponent of far-right President Jair Bolsonaro.

The Sao Paulo state government said in a statement it “regrets that it learned of the decision from the press, instead of directly from Anvisa”, and was waiting along with the Butantan Institute for more information on “the real reasons for the suspension”.

Pandemic politics

Bolsonaro has labelled CoronaVac the vaccine from “that other country”, and pushed instead for a rival vaccine developed by Oxford University and pharmaceutical firm AstraZeneca.

Last month, he shot down a plan by his own health minister to buy 46 million doses of CoronaVac, saying, “The Brazilian people will not be anyone’s guinea pig”, and referring to it as “Joao Doria’s Chinese vaccine”.

Doria announced earlier Monday that the first 120,000 doses of CoronaVac would arrive in Sao Paulo on Nov 20.

His state has a deal with Sinovac to buy a total of 46 million doses – six million produced in China and the rest produced in Sao Paulo, which broke ground last week on a factory to make the vaccine domestically.

“Officials in the state government fear Bolsonaro will use technical decisions to delay the timeline of the vaccine for political reasons,” newspaper Folha de Sao Paulo reported, citing unnamed Doria allies.

Anvisa told AFP it had no comment beyond its statement announcing the suspension, which said that halting trials was standard procedure in such cases.

Bolsonaro faces criticism for his handling of the pandemic, which has included downplaying the virus, opposing lockdown measures and relentlessly promoting the drug hydroxychloroquine despite studies showing it is ineffective against Covid-19.

The Sinovac, Pfizer and Oxford vaccines are all in Phase 3 trials, the final stage of testing before regulatory approval.

All are being tested in Brazil, the country with the second-highest death toll in the pandemic after the US, with more than 162,000 people killed by the new coronavirus.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

Chinese paper manufacturing giant committed to boosting Malaysia investment by RM5.4 billion, says PM

Muhyiddin Yassin says the increase in investment reflects the confidence of foreign investors in continuing to make Malaysia their destination of choice.

Tokyo asks China to end Covid-19 anal swabs for Japanese

Officials in China have used anal swabs to test people it considers at high-risk of contracting Covid-19, including residents of neighbourhoods with confirmed cases as well as some international travellers.

World won’t vanquish Covid-19 this year, WHO warns

WHO says it would be 'very premature' and 'unrealistic' to think that the world will be finished with Covid-19 by year-end.

Tech demand drove Asia’s factory revival from pandemic in February

But a slowdown in China underscored the challenges facing the region as it seeks a sustainable recovery from the Covid-19 pandemic.

Get back in line, Khairy warns after cases of politicians cutting vaccine queue

He says his ministry will recommend that the health ministry slap compounds on those who flout the rules.